After a bruising turn as Sarepta CEO, Chris Garabedian is back in biotech with a new role as godfather to a bunch of startups
Chris Garabedian is back.
Two years after the former Sarepta CEO ended a turbulent reign marked by a roller coaster ride for investors — which is still not over, even after the controversial FDA OK of eteplirsen — Garabedian has won $15 million from some loyal backers at Perceptive Advisors to establish a company that promises to guide biotech startups through that first critical stage of development leading to proof-of-concept data.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.